Leukemia: An Updated Review of Etiology, Pathogenesis, Clinical Manifestations, and Emerging Therapeutic Strategies

Leukemia: An Updated Review of Etiology, Pathogenesis, Clinical Manifestations, and Emerging Therapeutic Strategies

Abstract

Leukemia, a heterogeneous group of hematological malignancies characterized by the uncontrolled proliferation of abnormal leukocytes in the bone marrow and peripheral blood, remains a significant global health challenge. This review provides a comprehensive overview of leukemia, encompassing its diverse classifications, etiological factors, underlying pathogenic mechanisms, clinical presentation, diagnostic approaches, and current therapeutic strategies. We explore the genetic and environmental factors implicated in leukemogenesis, delve into the intricacies of leukemic cell signaling pathways, and discuss the challenges and advancements in conventional therapies such as chemotherapy and hematopoietic stem cell transplantation. Furthermore, we examine the promising landscape of novel therapeutic approaches, including targeted therapies, immunotherapies, and epigenetic modifiers, with a particular emphasis on their potential to improve patient outcomes and minimize treatment-related toxicities. Finally, we will discuss novel research involving GLP-1 receptor agonists and their possible effects on leukemia.

1. Introduction

Leukemia encompasses a spectrum of hematological malignancies characterized by the clonal expansion of abnormal hematopoietic progenitor cells in the bone marrow, leading to the suppression of normal hematopoiesis and the infiltration of malignant cells into various tissues and organs. The classification of leukemia is primarily based on the lineage of the affected hematopoietic cells (myeloid or lymphoid) and the disease’s clinical course (acute or chronic). Acute leukemias, such as acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL), are characterized by rapid disease progression and the accumulation of immature blast cells, while chronic leukemias, such as chronic myeloid leukemia (CML) and chronic lymphocytic leukemia (CLL), exhibit a more indolent course and the presence of more mature, albeit abnormal, leukocytes. Despite significant advances in diagnosis and treatment, leukemia remains a major cause of morbidity and mortality worldwide, highlighting the need for continued research to improve patient outcomes. This review aims to provide a comprehensive overview of leukemia, encompassing its etiology, pathogenesis, clinical manifestations, diagnostic modalities, current therapeutic strategies, and emerging therapeutic avenues.

2. Classification of Leukemia

Leukemia is classified into four main types based on the cell lineage affected and the disease’s rate of progression:

• Acute Myeloid Leukemia (AML): AML is characterized by the rapid proliferation of abnormal myeloid cells in the bone marrow and blood. It is the most common type of acute leukemia in adults and its incidence increases with age. AML is a heterogeneous disease, with various subtypes defined by specific genetic mutations and cytogenetic abnormalities, as defined by the World Health Organization (WHO) classification.

• Acute Lymphoblastic Leukemia (ALL): ALL is characterized by the rapid proliferation of abnormal lymphoid cells, primarily B- or T-cell precursors. It is the most common type of leukemia in children but can also occur in adults. ALL is further classified based on the immunophenotype of the leukemic cells and the presence of specific genetic abnormalities, such as the Philadelphia chromosome translocation t(9;22).

• Chronic Myeloid Leukemia (CML): CML is a myeloproliferative neoplasm characterized by the presence of the Philadelphia chromosome, resulting from a reciprocal translocation between chromosomes 9 and 22, which leads to the formation of the BCR-ABL1 fusion gene. This gene encodes a constitutively active tyrosine kinase that drives uncontrolled proliferation of myeloid cells. CML typically progresses through chronic, accelerated, and blast crisis phases.

• Chronic Lymphocytic Leukemia (CLL): CLL is characterized by the accumulation of mature, but functionally incompetent, B lymphocytes in the blood, bone marrow, and lymphoid tissues. CLL is the most common type of leukemia in adults and is often diagnosed incidentally during routine blood tests. The disease course can vary significantly, ranging from indolent to aggressive forms.

3. Etiology and Risk Factors

The etiology of leukemia is complex and multifactorial, involving a combination of genetic predisposition, environmental exposures, and lifestyle factors. While the exact causes of leukemia remain unknown for many individuals, several risk factors have been identified:

• Genetic Factors: Certain genetic syndromes, such as Down syndrome, Fanconi anemia, and Bloom syndrome, are associated with an increased risk of developing leukemia, particularly ALL and AML. Germline mutations in genes involved in DNA repair, hematopoiesis, and transcription regulation have also been implicated in leukemia susceptibility.

• Environmental Exposures: Exposure to ionizing radiation, such as that from radiation therapy or nuclear accidents, is a well-established risk factor for leukemia, particularly AML and CML. Exposure to certain chemicals, such as benzene, formaldehyde, and chemotherapeutic agents, has also been linked to an increased risk of leukemia.

• Previous Chemotherapy or Radiation: Treatment with certain chemotherapy drugs, especially alkylating agents and topoisomerase II inhibitors, can increase the risk of developing therapy-related leukemia (t-AML or t-ALL). Radiation therapy, particularly when combined with chemotherapy, also increases leukemia risk.

• Age: The incidence of most types of leukemia increases with age. AML and CLL are more common in older adults, while ALL is more common in children.

• Smoking: Smoking is associated with an increased risk of AML, particularly in individuals with certain genetic predispositions.

• Obesity and Diabetes: Emerging evidence suggests a potential link between obesity, type 2 diabetes, and an increased risk of certain hematological malignancies, including leukemia. Hyperinsulinemia, chronic inflammation, and alterations in adipokine levels associated with obesity and diabetes may contribute to leukemogenesis. This association could also explain some of the findings suggesting GLP-1 receptor agonists are associated with a decreased risk in some studies.

4. Pathogenesis of Leukemia

The pathogenesis of leukemia involves a complex interplay of genetic and epigenetic alterations that disrupt normal hematopoietic differentiation and proliferation, leading to the clonal expansion of malignant cells. Key mechanisms involved in leukemogenesis include:

• Genetic Mutations: Somatic mutations in genes involved in signal transduction, transcription regulation, DNA repair, and cell cycle control are frequently identified in leukemic cells. These mutations can lead to the activation of oncogenes or the inactivation of tumor suppressor genes, driving uncontrolled cell growth and proliferation. Common mutations in AML include those affecting FLT3, NPM1, CEBPA, and IDH1/2. In ALL, mutations affecting PAX5, IKZF1, and JAK-STAT signaling are frequently observed. The BCR-ABL1 fusion gene, resulting from the Philadelphia chromosome translocation, is a hallmark of CML.

• Epigenetic Modifications: Epigenetic alterations, such as DNA methylation and histone modifications, can also contribute to leukemogenesis by altering gene expression patterns. Aberrant DNA methylation patterns, including hypermethylation of tumor suppressor genes and hypomethylation of oncogenes, have been observed in various types of leukemia. Histone modifications, such as acetylation and methylation, can also influence gene expression and contribute to leukemic transformation.

• Disrupted Hematopoietic Differentiation: Leukemia is characterized by a block in hematopoietic differentiation, leading to the accumulation of immature blast cells. This differentiation block can be caused by mutations in transcription factors that regulate hematopoiesis, such as RUNX1, CEBPA, and PU.1. Aberrant epigenetic modifications can also contribute to the differentiation block by silencing genes required for normal hematopoietic differentiation.

• Microenvironment Interactions: The bone marrow microenvironment plays a crucial role in supporting the survival and proliferation of leukemic cells. Interactions between leukemic cells and stromal cells, extracellular matrix components, and cytokines in the bone marrow microenvironment can promote leukemic cell growth, drug resistance, and disease progression. This cross-talk often involves signaling pathways such as the PI3K/AKT/mTOR and NF-κB pathways.

• Immune Evasion: Leukemic cells can evade immune surveillance through various mechanisms, including downregulation of major histocompatibility complex (MHC) molecules, expression of immune checkpoint molecules such as PD-L1, and secretion of immunosuppressive cytokines. These mechanisms allow leukemic cells to escape recognition and elimination by the immune system.

5. Clinical Manifestations and Diagnosis

The clinical manifestations of leukemia can vary depending on the type of leukemia, the disease stage, and the extent of organ infiltration. Common signs and symptoms include:

• Fatigue and Weakness: Anemia, resulting from the suppression of normal erythropoiesis by leukemic cells, is a common cause of fatigue and weakness.

• Bleeding and Bruising: Thrombocytopenia, resulting from the suppression of normal megakaryopoiesis by leukemic cells, can lead to bleeding and bruising.

• Infections: Neutropenia, resulting from the suppression of normal granulopoiesis by leukemic cells, increases the risk of infections.

• Bone Pain: Infiltration of leukemic cells into the bone marrow can cause bone pain.

• Lymphadenopathy and Splenomegaly: Infiltration of leukemic cells into lymph nodes and the spleen can cause lymphadenopathy and splenomegaly.

• Weight Loss and Night Sweats: These symptoms are more common in chronic leukemias, particularly CML and CLL.

Diagnosis of leukemia typically involves a combination of:

• Complete Blood Count (CBC): A CBC can reveal abnormal white blood cell counts, anemia, and thrombocytopenia.

• Peripheral Blood Smear: Examination of a peripheral blood smear can identify abnormal leukocytes, such as blast cells.

• Bone Marrow Aspiration and Biopsy: Bone marrow aspiration and biopsy are essential for confirming the diagnosis of leukemia and determining the type of leukemia. These procedures allow for the evaluation of bone marrow cellularity, morphology, and cytogenetic abnormalities.

• Flow Cytometry: Flow cytometry is used to identify the immunophenotype of leukemic cells, which helps to classify the type of leukemia and assess minimal residual disease (MRD).

• Cytogenetic Analysis: Cytogenetic analysis, including karyotyping and fluorescence in situ hybridization (FISH), is used to detect chromosomal abnormalities, such as translocations, deletions, and inversions.

• Molecular Genetic Testing: Molecular genetic testing, such as PCR and next-generation sequencing (NGS), is used to identify specific gene mutations that are important for diagnosis, prognosis, and treatment selection. For example, identifying the BCR-ABL1 fusion gene is vital for CML diagnosis.

6. Current Treatment Strategies

The treatment of leukemia depends on the type of leukemia, the patient’s age and overall health, and the presence of specific genetic abnormalities. Standard treatment modalities include:

• Chemotherapy: Chemotherapy is the mainstay of treatment for most types of leukemia. Combination chemotherapy regimens are typically used to achieve remission, which is defined as the absence of detectable leukemic cells in the bone marrow. Chemotherapy agents commonly used in leukemia treatment include anthracyclines, cytarabine, vincristine, prednisone, and methotrexate. The specific chemotherapy regimen varies depending on the type of leukemia.

• Hematopoietic Stem Cell Transplantation (HSCT): HSCT is a potentially curative treatment option for certain types of leukemia, particularly AML and ALL. HSCT involves replacing the patient’s diseased bone marrow with healthy stem cells from a donor (allogeneic HSCT) or from the patient themselves (autologous HSCT). Allogeneic HSCT carries the risk of graft-versus-host disease (GVHD), in which the donor immune cells attack the recipient’s tissues. Reduced-intensity conditioning regimens are often used in older or less fit patients to minimize treatment-related toxicities.

• Targeted Therapies: Targeted therapies are drugs that specifically target molecules or pathways involved in leukemic cell growth and survival. Targeted therapies have revolutionized the treatment of certain types of leukemia, such as CML, where tyrosine kinase inhibitors (TKIs) like imatinib, dasatinib, and nilotinib are highly effective in inducing and maintaining remission by inhibiting the BCR-ABL1 tyrosine kinase activity. Other targeted therapies include FLT3 inhibitors for AML patients with FLT3 mutations, IDH1/2 inhibitors for AML patients with IDH1/2 mutations, and BCL-2 inhibitors for CLL patients.

• Immunotherapy: Immunotherapy harnesses the power of the immune system to fight cancer. Immunotherapy approaches used in leukemia treatment include:

  • Monoclonal Antibodies: Monoclonal antibodies, such as rituximab (anti-CD20) and alemtuzumab (anti-CD52), are used to target specific proteins on leukemic cells, leading to their destruction by the immune system.
  • Checkpoint Inhibitors: Checkpoint inhibitors, such as anti-PD-1 and anti-CTLA-4 antibodies, block immune checkpoint molecules that inhibit T cell activation, thereby enhancing the ability of T cells to kill leukemic cells. They have shown success in some relapsed or refractory leukemia cases.
  • CAR T-cell Therapy: Chimeric antigen receptor (CAR) T-cell therapy involves genetically engineering a patient’s T cells to express a CAR that recognizes a specific antigen on leukemic cells. The CAR T cells are then infused back into the patient, where they can specifically target and kill leukemic cells. CAR T-cell therapy has shown remarkable efficacy in relapsed or refractory ALL and is being investigated in other types of leukemia.

7. Emerging Therapeutic Strategies

Ongoing research is focused on developing novel therapeutic strategies to improve patient outcomes and minimize treatment-related toxicities in leukemia. Some promising emerging approaches include:

• Epigenetic Modifiers: Epigenetic modifiers, such as DNA methyltransferase inhibitors (DNMTis) and histone deacetylase inhibitors (HDACis), can reverse epigenetic alterations that contribute to leukemogenesis. These agents have shown activity in AML and are being investigated in combination with other therapies.

• Novel Targeted Therapies: New targeted therapies are being developed to target specific molecules and pathways involved in leukemic cell growth and survival. These include inhibitors of mutant IDH1/2, menin-MLL inhibitors, and inhibitors of other signaling pathways.

• Cellular Therapies: Research is ongoing to improve the efficacy and safety of cellular therapies, such as CAR T-cell therapy. This includes developing CAR T cells targeting novel antigens, optimizing CAR T-cell manufacturing processes, and addressing toxicities associated with CAR T-cell therapy, such as cytokine release syndrome (CRS) and neurotoxicity.

• MicroRNA-Based Therapies: MicroRNAs (miRNAs) are small non-coding RNA molecules that regulate gene expression. Aberrant miRNA expression has been implicated in leukemogenesis. MicroRNA-based therapies aim to restore normal miRNA expression patterns in leukemic cells, either by delivering synthetic miRNAs or by inhibiting endogenous miRNAs.

• Oncolytic Viruses: Oncolytic viruses are viruses that selectively infect and kill cancer cells. Oncolytic viruses are being investigated as a potential therapy for leukemia, either as a single agent or in combination with other therapies.

8. Potential role of GLP-1 receptor agonists in Leukemia prevention and treatment

Recent research has suggested a potential link between GLP-1 receptor agonists (GLP-1RAs), a class of drugs primarily used to treat type 2 diabetes, and a reduced risk of certain cancers, including some hematological malignancies. While the evidence is still emerging, the potential mechanisms underlying this association warrant further investigation:

• Anti-inflammatory Effects: GLP-1RAs have demonstrated anti-inflammatory effects by modulating immune cell activity and reducing the production of pro-inflammatory cytokines. Chronic inflammation is known to play a role in the development and progression of various cancers, including leukemia. By reducing systemic inflammation, GLP-1RAs may potentially mitigate the inflammatory milieu that promotes leukemogenesis.

• Modulation of Cell Proliferation and Apoptosis: Studies have shown that GLP-1RAs can influence cell proliferation and apoptosis in various cell types, including cancer cells. These drugs may directly inhibit the proliferation of leukemic cells or promote their programmed cell death (apoptosis) through mechanisms involving cell signaling pathways. In vitro experiments show that GLP-1RAs inhibit proliferation and reduce cell viability in AML cell lines [1].

• Regulation of Glucose Metabolism: GLP-1RAs improve glucose metabolism by stimulating insulin secretion, suppressing glucagon secretion, and increasing glucose uptake in peripheral tissues. Altered glucose metabolism is a hallmark of cancer cells, and targeting these metabolic pathways is an emerging area of cancer research. By normalizing glucose metabolism, GLP-1RAs may indirectly inhibit the growth and survival of leukemic cells.

• Immune Modulation: GLP-1RAs have been shown to modulate immune responses, including T cell function and natural killer (NK) cell activity. These immunomodulatory effects may enhance the ability of the immune system to recognize and eliminate leukemic cells. GLP-1RAs can enhance the activity of NK cells, which play a critical role in anti-tumor immunity, possibly enhancing the immunosurveillance against leukemia.

It is important to note that the current evidence linking GLP-1RAs to leukemia prevention and treatment is largely based on observational studies and preclinical data. Further research, including randomized controlled trials, is needed to confirm these findings and elucidate the underlying mechanisms of action. Furthermore, the potential role of GLP-1RAs in leukemia treatment needs to be carefully evaluated, considering the potential risks and benefits in the context of each patient’s individual clinical situation.

9. Conclusion

Leukemia remains a challenging hematological malignancy with diverse subtypes, complex pathogenesis, and variable clinical outcomes. While significant advances have been made in diagnosis and treatment, there is still a need for continued research to improve patient outcomes and minimize treatment-related toxicities. Emerging therapeutic strategies, such as targeted therapies, immunotherapies, and epigenetic modifiers, offer promising avenues for improving the treatment of leukemia. Furthermore, ongoing research into the etiology and pathogenesis of leukemia, including the potential role of factors like obesity, diabetes, and associated treatments like GLP-1RAs, may lead to new strategies for prevention and early detection. Further investigation is needed to validate the potential role of GLP-1RAs in leukemia prevention and treatment, as well as to elucidate the underlying mechanisms of action. A deeper understanding of the genetic and environmental factors that contribute to leukemogenesis is crucial for developing more effective and personalized treatment approaches. Future research should focus on identifying novel therapeutic targets, developing more precise diagnostic tools, and refining treatment strategies to improve the quality of life for patients with leukemia. Combining existing therapies in rational combinations, alongside innovative novel agents, holds the key to improving survival rates and ultimately curing more patients with leukemia.

References

[1] Zhao, R., He, R., Lu, X., Gao, Y., Shao, H., Guo, Y., … & Shen, Z. (2024). Liraglutide inhibits cell proliferation and reduces cell viability in acute myeloid leukemia cells. Frontiers in Pharmacology, 15, 1367933.

[2] Döhner, H., Estey, E. H., Grimwade, D., Amadori, S., Appelbaum, F. R., Büchner, T., … & Bloomfield, C. D. (2010). Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood, 115(3), 453-474.

[3] Hunger, S. P., & Mullighan, C. G. (2015). Acute lymphoblastic leukemia in children. New England Journal of Medicine, 373(16), 1541-1552.

[4] Faderl, S., Talpaz, M., Estrov, Z., O’Brien, S., Kurzrock, R., & Kantarjian, H. M. (1999). The biology of chronic myeloid leukemia. New England Journal of Medicine, 341(3), 164-172.

[5] Hallek, M., Cheson, B. D., Catovsky, D., Caligaris-Cappio, F., Dighiero, G., Döhner, H., … & Montserrat, E. (2018). iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood, 131(25), 2745-2760.

[6] Linet, M. S., Kim, D. S., Kitahara, C. M., & Berrington de González, A. (2015). Ionizing radiation and hematologic malignancies: a review. Leukemia & Lymphoma, 56(7), 1924-1931.

[7] Abeloff, M. D., Armitage, J. O., Niederhuber, J. E., Kastan, M. B., & McKenna, R. J. (Eds.). (2008). Clinical oncology. Elsevier Health Sciences.

[8] Papaemmanuil, E., Gerstung, M., Bullinger, L., Gaidzik, V. I., Paschka, P., Roberts, N. D., … & Campbell, P. J. (2016). Genomic classification and prognosis in acute myeloid leukemia. New England Journal of Medicine, 374(23), 2209-2221.

[9] Mullighan, C. G. (2012). The molecular genetic makeup of acute lymphoblastic leukemia. Blood, 120(26), 5182-5193.

[10] Lane, S. W., Steelman, A. J., Cooley, H. M., & Parslow, A. C. (2009). Stromal cell-derived factor-1 (SDF-1) and c-Kit ligand (SCF) synergistically promote primitive human hematopoietic cell survival and proliferation: distinct signaling pathways and implications for stem cell grafting. Blood, 113(5), 1007-1016.

[11] June, C. H., Sadelain, M., & Rosenberg, S. A. (2017). CAR T-cell therapy. New England Journal of Medicine, 378(1), 64-73.

[12] Estey, E. (2011). Acute myeloid leukemia: 2011 update on diagnosis, risk stratification, and management. American Journal of Hematology, 86(1), 68-77.

[13] Short, N. J., Rytting, M. E., & Cortes, J. E. (2018). Acute myeloid leukemia: a concise review. Journal of Clinical Medicine, 7(10), 241.

[14] O’Brien, S., & Letak, F. (2024). GLP-1 receptor agonists and cancer: A review of the literature. Obesity. (Early View).